First-pass hydrolysis of a propranolol ester derivative in rat small intestine

Drug Metabolism and Disposition

Volumn 34, Issue 3, 2006, Pages 398-404

  Masaki, Kenji ^a   Taketani, Megumi ^a   Imai, Teruko ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ESTER DERIVATIVE; O ISOVALERYL PROPRANOLOL; PROPRANOLOL; PROPRANOLOL DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BLOOD VESSEL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DEGRADATION; DRUG ELIMINATION; DRUG HYDROLYSIS; DRUG PENETRATION; DRUG TRANSPORT; DRUG UPTAKE; EPITHELIUM CELL; FIRST PASS EFFECT; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINE PERFUSION; JEJUNUM; LIPOPHILICITY; MALE; MATHEMATICAL COMPUTING; MEMBRANE PERMEABILITY; NONHUMAN; PH MEASUREMENT; PRIORITY JOURNAL; RAT; SMALL INTESTINE;

ANIMALS; CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; HYDROLYSIS; INTESTINAL ABSORPTION; INTESTINAL MUCOSA; JEJUNUM; MALE; METABOLIC DETOXICATION, DRUG; PERFUSION; PROPRANOLOL; RATS; RATS, WISTAR;

ANIMALIA;

EID: 33344466381     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.105.007682     Document Type: Article

References (36)

1. Amidon GL, Sinko PJ, and Fleisher D (1988) Estimating human oral fraction dose absorbed: a correlation using rat intestinal membrane permeability for passive and carrier-mediated compounds. Pharm Res (NY) 5:651-654.
2. Bencharit S, Morton CL, Howard-Williams EL, Danks MK, Potter PM, and Redinbo MR (2002) Structural insights into CPT-11 activation by mammalian carboxylesterases. Nat Struct Biol 9:337-342.
3. Bencharit S, Morton CL, Xue Y, Potter PM, and Redinbo MR (2003) Structural basis of heroin and cocaine metabolism by a promiscuous human drug-processing enzyme. Nat Struct Biol 10:349-356.
4. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
5. Collett A, Tanianis-Hughes J, and Warhurst G (2004) Rapid induction of P-glycoprotein expression by high permeability compounds in colonic cells in vitro: a possible source of transporter mediated drug interactions? Biochem Pharmacol 68:783-790.
6. D'Emanuele A, Jevprasesphant R, Penny J, and Attwood D (2004) The use of a dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral bioavailability. J Controlled Release 95:447-453.
7. Fagerholm U, Johansson M, and Lennernäs H (1996) Comparison between permeability coefficients in rat and human jejunum. Pharm Res (NY) 13:1336-1342.
8. Holtbecker N, Fromm MF, Kroemer HK, Ohnhaus EE, and Heidemann H (1996) The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. Drug Metab Dispos 24:1121-1123.
9. Kaminsky LS and Zhang QY (2003) The small intestine as a xenobiotic-metabolizing organ. Drug Metab Dispos 31:1520-1525.
10. Lin JH, Chiba M, and Baillie TA (1999) Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol Rev 51:135-158.
11. Lucas M (1983) Determination of acid surface pH in vivo in rat proximal jejunum. Gut 24:734-739.
12. Lucas ML, Schneider W, Haberich FJ, and Blair JA (1975) Direct measurement by pH-microelectrode of the pH microclimate in rat proximal jejunum. Proc R Soc Lond B Biol Sci 192:39-48.
13. Mizen L and Burton G (1998) The use of esters as prodrugs for oral delivery of β-lactam antibiotics. Pharm Biotechnol 11:345-365.
14. Neuhoff S, Ungell AL, Zamora I, and Artursson P (2003) pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions. Pharm Res (NY) 20:1141-1148.
15. Okudaira N, Tatebayashi T, Speirs GC, Komiya I, and Sugiyama Y (2000) A study of the intestinal absorption of an ester-type prodrug, ME3229, in rats: active efflux transport as a cause of poor bioavailability of the active drug. J Pharmacol Exp Ther 294:580-587.
16. Pang KS, Yuen V, Fayz S, te Koppele JM, and Mulder GJ (1986) Absorption and metabolism of acetaminophen by the in situ perfused rat small intestine preparation. Drug Metab Dispos 14:102-111.
17. Prueksaritanont T, DeLuna P, Gorham LM, Ma B, Cohn D, Pang J, Xu X, Leung K, and Lin JH (1998) In vitro and in vivo evaluations of intestinal barriers for the zwitterion L-767,679 and its carboxyl ester prodrug L-775,318. Roles of efflux and metabolism. Drug Metab Dispos 26:520-527.
18. Ruiz-Balaguer N, Nacher A, Casabo VG, and Merino Sanjuan M (2002) Intestinal transport of cefuroxime axetil in rats: absorption and hydrolysis processes. Int J Pharm 234:101-111.
19. Salama NN, Scott KR, and Eddington ND (2004) DM27, an enaminone, modifies the in vitro transport of antiviral therapeutic agents. Biopharm Drug Dispos 25:227-236.
20. Satoh T and Hosokawa M (1998) The mammalian carboxylesterases: from molecules to functions. Annu Rev Pharmacol Toxicol 38:257-288.
21. Shameem M, Imai T, and Otagiri M (1993) An in-vitro and in-vivo correlative approach to the evaluation of ester prodrugs to improve oral delivery of propranolol. J Pharm Pharmacol 45:246-252.
22. Shiau YF, Fernandez P, Jackson MJ, and McMonagle S (1985) Mechanisms maintaining a low-pH microclimate in the intestine. Am J Physiol 248:G608-G617.
23. Tamura S, Tokunaga Y, Ibuki R, Amidon GL, Sezaki H, and Yamashita S (2003) The site-specific transport and metabolism of tacrolimus in rat small intestine. J Pharmacol Exp Ther 306:310-316.
24. Taylor DC, Pownall R, and Burke W (1985) The absorption of β-adrenoceptor antagonists in rat in-situ small intestine; the effect of lipophilicity. J Pharm Pharmacol 37:280-283.
25. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, and Wilkinson GR (1996) Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 59:491-502.
26. Ungell AL, Nylander S, Bergstrand S, Sjöberg Å, and Lennernäs H (1998) Membrane transport of drugs in different regions of the intestinal tract of the rat. J Pharm Sci 87:360-366.
27. Wadkins RM, Morton CL, Weeks JK, Oliver L, Wierdl M, Danks MK, and Potter PM (2001) Structural constraints affect the metabolism of 7-ethyl-10-[4-(1- piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) by carboxylesterases. Mol Pharmacol 60:355-362.
28. Wu CY, Benet LZ, Hebert MF, Gupta SK, Rowland M, Gomez DY, and Wacher VJ (1995) Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther 58:492-497.
29. Yamaoka K, Tanigawara Y, Nakagawa T, and Uno T (1981) A pharmacokinetic analysis program (MULTI) for microcomputer. J Pharmacobio-Dyn 4:879-885.
30. Yamashita S, Tanaka Y, Endoh Y, Taki Y, Sakane T, Nadai T, and Sezaki H (1997) Analysis of drug permeation across Caco-2 monolayer: implication for predicting in vivo drug absorption. Pharm Res (NY) 14:486-491.
31. Yamashita S, Yoshida M, Taki Y, Sakane T, and Nadai T (1994) Kinetic analysis of the drug permeation process across the intestinal epithelium. Pharm Res (NY) 11:1646-1651.
32. Yang JJ, Kim KJ, and Lee VH (2000) Role of P-glycoprotein in restricting propranolol transport in cultured rabbit conjunctival epithelial cell layers. Pharm Res (NY) 17:533-538.
33. Yoshigae Y, Imai T, Aso T, and Otagiri M (1998) Species differences in the disposition of propranolol prodrugs derived from hydrolase activity in intestinal mucosa. Life Sci 62:1231-1241.
34. Yoshigae Y, Imai T, Taketani M, and Otagiri M (1999) Characterization of esterases involved in the stereoselective hydrolysis of ester-type prodrugs of propranolol in rat liver and plasma. Chirality 11:10-13.
35. Zhang W, Xu G, and McLeod HL (2002) Comprehensive evaluation of carboxylesterase-2 expression in normal human tissues using tissue array analysis. Appl Immunohistochem Mol Morphol 10:374-380.
36. Zimmerman CL, Wen Y, and Remmel RP (2000) First-pass disposition of (-)-6-aminocarbovir in rats: II. Inhibition of intestinal first-pass metabolism. Drug Metab Dispos 28:672-679.